June 25, 2017 (VJHemOnc)
CAR T-cells seem to be taking the hematology world by storm. Here. Rakesh Popat, MD, PhD from the University College London, London, UK talks to us about the different approaches being taken in multiple myeloma, such as the novel 3td generation CAR T-cell construct BB2121, and a novel unnamed construct from Legend Biotech, both targeting the B-cell maturing antigen (BCMA). In the UK, Dr Rakesh’ group is working on an different approach to targeting BCMA, by using APRIL, a natural bi-specific binding molecule of BCMA and TACI. Despite the deep and durable responses to this type of immunotherapy, side effects are still present and should be monitored closely.
